Victory Capital Management
LSTA icon

Victory Capital Management’s Lisata Therapeutics LSTA Stock Holding History

Victory Capital Management’s Portfolio LSTA Stock Details LSTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-195
Closed -$6K – 2931
2020
Q1 		$6K Buy
+195
New +$7.56K ﹤0.01% 3435
2019
Q4 		– Sell
-109
Closed -$4K – 2986
2019
Q3 		$4K Buy
+109
New +$4.24K ﹤0.01% 3509

Other funds holding LSTA

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
STA
Summit Trail Advisors New York $6.98B AUM 19.51% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
WB
WesBanco Bank Wheeling, West Virginia $3.61B AUM 24.09% 1-Year Est. Return

Victory Capital Management's LSTA Position: Q2 2020 in Review

Victory Capital Management sold out of Lisata Therapeutics (LSTA) in Q2 2020, closing a stake of 195 shares — an estimated $6K sold.

Victory Capital Management first reported a position in LSTA in Q3 2019 and held it in 2 quarters. The position peaked at $6K in Q1 2020. 24 funds tracked by Wall St. Rank hold LSTA as of Q2 2020.

  • Victory Capital Management reported no remaining Lisata Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Victory Capital Management sold 195 Lisata Therapeutics shares in Q2 2020, an estimated $6K.
  • Victory Capital Management first reported a position in Lisata Therapeutics in Q3 2019 and held it in 2 quarters.
  • Victory Capital Management's Lisata Therapeutics position peaked at $6K in Q1 2020.
  • 24 funds tracked by Wall St. Rank held Lisata Therapeutics as of Q2 2020.

Based on Victory Capital Management's 13F filing for Q2 2020, filed 7 Aug 2020.